3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Osteosarcoma
3
Neuroblastoma
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Stomach Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive
1
Nerve Sheath Neoplasms
1
Myoepithelioma
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Giant Cell Tumor of Bone
1
Desmoplastic Small Round Cell Tumor
1
Chordoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Ascites
1
Adenocarcinoma
1
Interventions
Oxaliplatin
10
pembrolizumab
8
Fluorouracil
8
Leucovorin
7
Paclitaxel
5
Gemcitabine
5
Docetaxel
5
Capecitabine
5
Cyclophosphamide
4
Blood Specimen Collection
4
zolbetuximab
3
fludarabine
3
darolutamide
3
cemiplimab
3
Trastuzumab
3
Taxes
3
Ramucirumab
3
Radiotherapy
3
Radiosurgery
3
Irinotecan
3
trastuzumab deruxtecan
2
enzalutamide
2
durvalumab
2
Standard of Care
2
Nivolumab
2
Folfox protocol
2
Dexamethasone
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adenocarcinoma
×
Zoledronic Acid
×
Clear all
NCT06759064
2025-11-19
IPIZA
Qilu Hospital of Shandong University
Phase 1/2
Recruiting
24 enrolled